YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Synthesis of (${\pm}$)-cis-8-amino-l-2,3,4,4a,5,10b-hexahydrothiazolo[4,5-f]indeno [1,2-b][1,4]oxazine

(${\pm}$)-cis-8-Amino-2,3,4,4a,5,10b-hexahydrothiazolo[4,5-f]indeno [1,2-b][1,4]oxazine의 합성

  • Ma, Eun-Sook (College of Pharmacy, Catholic University of Daegu)
  • 마은숙 (대구가톨릭대학교 약학대학)
  • Published : 2008.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

2-Aminothiazole ring as a bioisoster of catechol in dopamine has provided with good oral availability and lipophilic property. 2-Aminoindan, is a rigid form of dopamine, was evaluated as a dopamine D3 agonist with low neurotoxicity. Dopamine D3 agonist was evaluated as selective for the treatment of Parkinson's disease. In order to develop a novel dopamine D3 agonist, we tried to synthesize the aminothiazoloindenoxazine derivative that is a hybrid structure of aminoindenoxazine and thiazole ring. cis-2-Amino-1-indanol (2) was synthesized from 1,2-indandione-2-oxime by catalytic hydrogenation and it was treated with chloroacetyl chloride and NaH in benzene solution to give (${\pm}$)-cis-4,4a,5,9b-tetrahydroindeno[1,2-b][1,4]oxazin-3(2H)-one (6). Nitration of 6 by the mixed acid gave 8-nitro compound (7) and the carbonyl group of 7 was reduced with $LiAlH_4$ to afford compound (8). 8 was reduced to form (${\pm}$)-cis-8-amino-2,3,4,4a,5,9b-hexahydroindeno[1,2-b][1,4]oxazine (9) and finally it was cyclized with KSCN in glacial acetic acid to yield (${\pm}$)-cis-8-amino-2,3,4,4a,5,10b-hexahydrothiazolo[4,5-f]indeno[1,2-b][1,4]oxazine (10).

Keywords

References

  1. Kebabian, J. W. and Calne, D. B. : Multiple receptors for dopamine. Nature 277, 93 (1979) https://doi.org/10.1038/277093a0
  2. Levant, B. : The $D_3$ dopamine receptor; Neurobiology and potential clinical relevance. Pharmacol. Rev. 49(3), 231 (1997)
  3. Jean, J. C., Wise, L. D., Caprathe, B. W., Tecle, H., Bergmeier, S., Humblet, C. C., Heffner, T. G., Meltzer, L. T. and Pugsley, T. A. : 4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: a novel class of compounds with central dopamine agonist properties. J. Med. Chem. 33, 311 (1990) https://doi.org/10.1021/jm00163a051
  4. Mierau, J., Schnider, F. J., Ensinger, H. A., Chio, C. L., Lajiness, M. E. and Huff, R. M. : Pramipexole binding and activation of cloned and expressed dopamine $D_2,\;D_3\;and\;D_4$ receptor. Eur. J. Pharmacol. 290, 29 (1995) https://doi.org/10.1016/0922-4106(95)90013-6
  5. James, P. B. Jr. and Montford, E. P. : Pramipexole-a new dopamine agonist for the treatment of Parkinson's disease. J. Neuro. Sci. 163, 25 (1999) https://doi.org/10.1016/S0022-510X(98)00307-4
  6. Bonne, C., Latour, E., Muller, P., Kozak, Y., Fature, J. P., Malet, F., Colin, J., Tissot, M., Giroud, J. P., Maghni, K., Griswold, D. E. and Coquelet, C. : 2-(2-Hydroxy-4-methylphenyl) aminothiazole hydrochloride as a inhibitor of cyclooxygenase and a free radical scavenger. 2nd communication: anti-inflammatory activity. Arzneimittelforschung 39, 1246 (1981)
  7. Hall, E. D., Andrus, P. K., Oostveen, J. A., Althaus, J. S. and Vonvoigtlander, P. F. : Neuroprotective effects of the dopamine $D_2/D_3$ agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res. 742, 80 (1996) https://doi.org/10.1016/S0006-8993(96)00968-7
  8. Haadsma-Syensson, S. R., Cleek, K. A., Dinh, D. M., Duncan, J. N., haber, C. L., Huff, R. M., Lajiness, M. E., Nichols, N. F., Smith, M. W., Svensson, K. A., Zaya, M. J., Carlsson, A. and Lin, C.-H. : Dopamine D3 receptor antagonists, 1. Synthesis and structure-activity relationshilps of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-1-substituted-2-aminoindans. J. Med. Chem. 44, 4716 (2001) https://doi.org/10.1021/jm010145w
  9. Hacksell, U., Arvidsson, L. E., Svensson U., Nilsson, J. L., Wilstrom, H., Lindberg, P., Sanchez, D., Hjorth, S., Carlsson, A. and Paalzow, L. : Monophenolic 2-(dipropylamino)indans and related compounds: central dopamine-receptor stimulating activity. J. Med. Chem. 24, 429 (1981) https://doi.org/10.1021/jm00136a012
  10. Watts, R. L. : The role of dopamine agonists in early Parkinson's disease. Neurology 49, S34 (1997) https://doi.org/10.1212/WNL.49.1_Suppl_1.S34
  11. DeWald, H. A., Heffner, T. G., Jaen, J. C., Lustgarten, D. M., McPhail, A. T., Meltzer, L. T., Pugsley, T. A. and Wise, L. D. : Synthesis and dopamine agonist properties of (+)-trans-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazine-9-ol and its enantiomers. J. Med. Chem. 33, 445 (1990) https://doi.org/10.1021/jm00163a068
  12. Pugsley, T. A., Davis, M. D., Akunne, H. C., MacKenzie, R. G., Shin, Y. H., Damsma, G., Wikstrom, H., Whetzel, S. Z., Georgic, L. M., Cooke, L. W., Demattos, S. B., Corbin, A. E., Glass, S. A., Wise, L. D., Dijkstra, D. and Heffner, T. G. : Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J. Pharmacol. Exp. Ther. 275, 1355 (1995)
  13. Dijkstra, D., Mulder, T. B., Rollema, H., Tepper, P. G., Van der Weide, J. and Horn, A. S. : Synthesis and pharmacology of trans-4-n-propyl-3,4,4a,10b-tetrahydro-2H,5H-1-benzopyrano[4,3-b]-1,4-oxazin-7- and 9-ols: the significance of nitrogen pKa values for central dopamine receptor activation. J. Med. Chem. 31, 2178 (1988) https://doi.org/10.1021/jm00119a020